---
title: "Lutonix AV global registry shows higher target lesion primary patency when considered under IDE criteria"
date: "2024-08-13T13:48:38.000Z"
publishedDate: "13 août 2024"
summary: "In a new post-hoc analysis of the Lutonix (BD) arteriovenous (AV) global registry using investigational device exemption (IDE) criteria, Dimitrios Karnabatidis (Patras University Hospital, Patras, Greece) reports the “highest” six-month target lesion primary patency (TLPP) to date when evaluated through IDE criteria, presented at the Endo Vascular Access (EVA) meeting (14-15 June, Patras, Greece). As [&#8230;] The post Lutonix AV global registry shows higher target lesion primary patency when considered under IDE criteria appeared first on Interventional News ."
importance: ""
sourceUrl: "https://interventionalnews.com/lutonix-av-global-registry-shows-higher-target-lesion-primary-patency-when-considered-under-ide-criteria/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2024-08-13-lutonix-av-global-registry-shows-higher-target-lesion-primary-patency-when-considered-under-ide-criteria"
imageUrl: "http://interventionalnews.com/wp-content/uploads/sites/13/2024/08/WhatsApp-Image-2024-07-02-at-14.47.04_7a980728.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/lutonix-av-global-registry-shows-higher-target-lesion-primary-patency-when-considered-under-ide-criteria/"
---

![Lutonix AV global registry shows higher target lesion primary patency when considered under IDE criteria](http://interventionalnews.com/wp-content/uploads/sites/13/2024/08/WhatsApp-Image-2024-07-02-at-14.47.04_7a980728.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/lutonix-av-global-registry-shows-higher-target-lesion-primary-patency-when-considered-under-ide-criteria/*

## L’essentiel

In a new post-hoc analysis of the Lutonix (BD) arteriovenous (AV) global registry using investigational device exemption (IDE) criteria, Dimitrios Karnabatidis (Patras University Hospital, Patras, Greece) reports the “highest” six-month target lesion primary patency (TLPP) to date when evaluated through IDE criteria, presented at the Endo Vascular Access (EVA) meeting (14-15 June, Patras, Greece). As [&#8230;] The post Lutonix AV global registry shows higher target lesion primary patency when considered under IDE criteria appeared first on Interventional News .

## Lien source

https://interventionalnews.com/lutonix-av-global-registry-shows-higher-target-lesion-primary-patency-when-considered-under-ide-criteria/
